STOCK TITAN

89bio, Inc. - $ETNB STOCK NEWS

Welcome to our dedicated page for 89bio news (Ticker: $ETNB), a resource for investors and traders seeking the latest updates and insights on 89bio stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 89bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 89bio's position in the market.

Rhea-AI Summary
89bio, Inc. (ETNB) to participate in fireside chat at Evercore HEALTHCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
conferences
-
Rhea-AI Summary
89bio, Inc. (Nasdaq: ETNB) announces new data from ENLIVEN Phase 2b trial on pegozafermin treatment for F4 NASH patients. Results show improvements in liver specific biomarkers, fibrosis, and inflammation, with a responder analysis suggesting a correlation between NIT-based improvements and histological measures. Safety profile remains favorable. The company plans to initiate Phase 3 program in the first half of next year pending regulatory feedback.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
89bio, Inc. (ETNB) has been granted Breakthrough Therapy Designation (BTD) for pegozafermin in treating NASH with fibrosis. The company expects regulatory feedback on its Phase 3 development program this quarter. Data from ENLIVEN in patients with cirrhotic (F4) NASH will be presented at AASLD. Financial results for Q3 2023 show $448.3 million in cash and a net loss of $34.7 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.86%
Tags
Rhea-AI Summary
89bio to participate in H.C. Wainwright NASH Investor Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
conferences
-
Rhea-AI Summary
89bio approves grant of non-qualified stock options to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
none
-
Rhea-AI Summary
FDA grants Breakthrough Therapy Designation to pegozafermin in NASH patients, positive data from Phase 2b trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.82%
Tags
none
Rhea-AI Summary
89bio, Inc. to participate in fireside chat and investor meetings at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.84%
Tags
conferences
-
Rhea-AI Summary
89bio, Inc. announces participation in H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
conferences
-
Rhea-AI Summary
89bio, Inc. (Nasdaq: ETNB) reported positive results from Phase 2 trials of pegozafermin in NASH and SHTG, with plans to initiate Phase 3 trials. The company published data from the ENLIVEN Phase 2b trial in The New England Journal of Medicine, validating the therapeutic utility of pegozafermin. Discussions with regulatory agencies for Phase 3 NASH program are planned for the second half of 2023. The ENTRUST Phase 3 trial of pegozafermin in patients with severe hypertriglyceridemia (SHTG) has been initiated, and the Phase 2 ENTRIGUE trial results were published in Nature Medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.34%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
89bio, Inc.

Nasdaq:ETNB

ETNB Rankings

ETNB Stock Data

849.05M
69.50M
0.86%
106.21%
12.35%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN FRANCISCO

About ETNB

89bio, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. its lead product candidate is bio89-100, a glycopegylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. the company also intends to develop bio89-100 for the treatment of severe hypertriglyceridemia. 89bio, inc. was founded in 2018 and is based in san francisco, california.